Connect with us


October 2022 Monthly

The historic dollar rally accelerated in September. By some measures, it is as rich as it has been in the half-century since the end of Bretton Woods….



The historic dollar rally accelerated in September. By some measures, it is as rich as it has been in the half-century since the end of Bretton Woods. Persistent price pressures, a robust labor market in many dimensions, and the Federal Reserve's latest forecasts warn that financial conditions will tighten into next year. However, we suspect that the market may have seen peak Fed hawkishness when it briefly priced in a terminal Fed funds rate of around 5.50% towards the middle of the next year. As September drew to a close, the market had re-adjusted and returned to about a 4.50% peak rate by the end of Q1 23. After dramatic gains in September, we anticipate a corrective/consolidative phase in October for the dollar.

The moves of the nominal exchange rates, as momentous as they may be, might not capture the magnitude of the overshoot that is taking place. According to the OECD's measure of purchasing power parity, the euro and yen are at historic under-valuation levels of almost 45% and 44%, respectively. Sterling is nearly 30% undervalued. Consider that the major currencies rarely deviate more than 20% from the OECD's fair value (PPP).   In the past, such an over-valuation of the dollar would spark concern by some US industries of unfair advantage to European and Japanese producers. Some multinational companies cite the decline in the dollar value of their foreign earnings, but the broader pushback has been minimal.  

US goods exports reached record levels in July despite the dollar's strength before slipping slightly in August. More and higher priced energy shipments have made up for slower growth in other goods shipments. Imports fell for five months through August and are off 6% from the record high set in March. This sucks away some of the oxygen of potential protectionist sentiment that has been heard in past periods of solid dollar appreciation.

Unlike the last big dollar rally in the mid-1990s, when then-Treasury Secretary Robert Rubin initiated the firm dollar policy, the current administration has been reluctant to resurrect the language. Some feared that it had lost its meaning and/or was confusing. However, the strong dollar policy is alive and well at the Federal Reserve. The dollar's strength is understood to be one of the channels through which the rate hikes tighten financial conditions, which in turn is to help bring demand back into line with the supply constraints. As a result, US officials have shown little interest in a Plaza-like agreement (to drive the dollar down as in 1985) that some think is necessary. 

Depending on where you sit, the Fed is either the hero or the villain of the bullish dollar narrative. However, there might be more to it than that. The eurozone and Japan are experiencing a dramatic deterioration of their external balances. Consider the recent trade reports. The eurozone's average trade deficit in the first seven months of the year was 25.3 bln euros. For the same period last year, it had an average monthly surplus of 16.6 bln euros. In the Jan-July period in 2019, the average surplus was larger, near 21 bln euros. Japan's latest trade figures cover August, and this year Japan has recorded an average monthly deficit of JPY1.53 trillion (~$11 bln). In the same period last year, it averaged a monthly surplus of JPY73 bln. 

Without getting too far ahead of ourselves, the forces that will change this, even if it takes a bit more time, have been set into play. The price of money adjusts quickly compared with the price of goods, trade flows, and investment flows. The unprecedented extreme valuations will encourage a change in the behaviors of businesses and households. They will be part of the broader narrative when the (dollar's) bull market ends.   

In 2008, a famous fashion model demanded to be paid in euros instead of dollars. A rap artist featured euros in a video. The press and financial research were full of eulogies for the dollar. We suspect that type of extreme sentiment, but its opposite, is being seen now, with claims that there is no alternative to the dollar, Europe is "uninvestable," or sterling is an emerging market currency.

Despite the US economy having contracted in H1 22, and the median Fed forecast chopped this year's growth estimate to 0.2% from 1.7% in June, the US appears to be emerging from Covid, the energy crisis, and Russia's invasion of Ukraine in a stronger position compared its allies and competitors. Yet, the insistence that cyclical forces are structural often seems to provide the last fuel for the move and, to mix metaphors, the last drop of tea that overflows the cup.

China is having a particularly difficult time. Most of it is homegrown. As Xi brought the tech giants to heel, the regulatory crackdowns used anti-corruption campaigns to get rid of opposition, coupled with the zero-Covid policy, have weakened the growth profile. In addition, its Covid vaccine was reportedly less effective than the ones more common in the US and Europe. The vaccination rate appears relatively low and slow to roll out boosters. 

Russia's invasion of Ukraine also may be encouraging foreign businesses to re-think exposure to China. The UN report on Xingjian, human rights violations, confirmed what many suspected. The property market, a significant driver of economic growth and development, has been hobbled and is still bleeding. In this context, Xi is expected to be granted a third term at the 20th People's Congress in mid-October. The PBOC has introduced measures meant to slow the yuan's depreciation. 

Among the G10 countries, Japan stands out. It still has a negative policy rate, and not only has it not raised rates, but Bank of Japan Governor Kuroda also insists that policy will not change soon. A few days after the BOJ increased its bond-buying (expanding its balance sheet), the Federal Reserve delivered the 75 bp hike. As a result, the dollar surged above JPY145, and the Ministry of Finance intervened to support the yen for the first time since 1998. However, the intervention did not meet the three conditions that would boost the chance of success: surprise, multilateral, and a signal of a policy change.

The BOJ policy appears riddled with contradictions, including adjusting the foreign exchange rate while fixing interest rates under Yield Curve Control. The intervention did stem the dollar's appreciation but could not knock it below JPY140, which means that it was unlikely to have inflicted the kind of pain that would discourage further yen weakness. Volatility did not subside very much, either. Benchmark three-month implied volatility set a high before the intervention near 13.4%. It was near 12.3% at the end of September, which is still more than twice the year-ago level. 

Japanese policymakers may have complained the most in the G10 about the dollar's strength, yet even before the September 22 intervention, it was not the weakest or most volatile currency among the G10. By September 21, the yen was off nearly 3.5% for the month. The Swedish krona was off 3.7%, the Norwegian krone was down almost 4.1%, and the New Zealand dollar had lost more than 4.3%. Sterling had traded at its lowest level since 1985, while the yen was at its weakest since 1998. The three-month implied volatility (embedded in option prices) for the yen on September 21 was 11.1%. The Scandinavian and Antipodean currencies were more volatile, and the euro's volatility (10%) was not significantly different.  

Aside from the Bank of Japan, central bankers have persuaded investors that the need to get inflation in check is the paramount objective, even if it means economic pain. As a result, higher interest rates and weaker growth are anticipated. However, the pace of tightening may moderate soon. Among the G10, both the Bank of Canada and the Reserve Bank of Australia have been explicit about this, and the Fed may have another 75 bp hike in it, but it too is seen slowing the tightening later in Q4.

The European Central Bank may hike by 125-150 bp in Q4, while the new UK government's aggressive fiscal policy will most likely spur the Bank of England to raise rates more forcefully, maybe 150 bp, though it does not meet until November 3. Even before Truss-Kwarteng's mini-budget, many expected the BOE to move quicker than the two half-point moves delivered in August and September. Three of the nine MPC ministers favored a 75 bp hike in September.  

Truss had campaigned for Tory Party leadership at least in part by advocating an unwinding of the tax increases of the Johnson-Sunak government. When she carried through her promises, investors seemed gobsmacked. While some observers noted that fiscal and monetary policy were moving in opposite directions, we see similarities with the policy of Reagan-Volcker, or when the Berlin Wall fell (leading to the uber-mark, which eventually paved the way for the European Economic and Monetary Union itself). More recently, former US President Trump delivered significant tax cuts as the Federal Reserve was tightening policy. While the Truss government is taking a considerable gamble, expanding fiscal policy and tighter monetary policy has often seen the respective currency appreciate over time. 

The relationship between currencies and policy rates is more complicated than it may seem looking at the yen's weakness. The Bank of England raised rates more than twice much as the Swiss National Bank. As a result, the Swiss franc eclipsed the Canadian dollar in September as the strongest major currency this year, and sterling is among the weakest. Sweden's Riksbank delivered a 100 bp hike last month, and the krona sold off to new record lows.   

The dollar rose against most emerging market currencies in September.    The JP Morgan Emerging Market Currency Index fell by about 3.2% in September, which brought the year-to-date loss to 7.8%. The theme for most of this year has been the outperformance of Latin American currencies. It stalled in September. The Mexican peso posted a minor gain (less than 0.2%), making it the second best performer among emerging market currencies after the Russian rouble. Brazil, which had been a market favorite, succumbed to pressure ahead of the presidential election. Leaving aside the Hong Kong dollar, three of the top five performing emerging market currencies in Q3 were from Latam:  Brazil, Mexico, and Peru.  

Bannockburn's World Currency Index, a GDP-weighted basket of the currencies representing the 12 largest economies, fell slightly more than 2% in September as all but the Russian rouble and Mexican peso fell against the dollar.   The BWCI took out the 2020 low. With a strong dollar, tighter Fed policy, and economic weakness in China, one may have expected emerging market currencies to have fared worse than the G10. Yet that is not what is happening. In September, the major currencies in the index fell by an average of 4.4% (excluding the dollar), and the emerging market currencies in the index fell by about 2.5%. 

Dollar:   The labor market's resilience boosts the Federal Reserve's confidence to raise rates to bring inflation back to its target. Encouraged by the latest Fed projections, the market looks for a 75 bp hike in November to be the last of that size before slowing to 50 bp in December. Most of the heavy lifting will be done this year, but rates are expected to be hiked in Q1 23 when the market sees the peak. The Fed anticipates cutting rates in 2024 while the market continues to lean toward a cut late next year. Inflation may be near its peak, but rents and medical services will likely keep core inflation sticky. The dollar's appreciation will reduce the value of foreign earnings for US multinational companies. Nevertheless, the dollar's appreciation is one of the channels through which financial conditions are tightening. As a result, we expect the dollar to be more vulnerable as the end of the monetary cycle approaches.  

Euro:  The eurozone economy is on the edge of a recession. The energy shock and broader cost-of-living squeeze are taking a toll, yet with inflation at 10%, the European Central Bank has little choice but to continue to tighten policy. After a 50 bp hike in July, the ECB hiked by 75 bp in September, and it looks poised to deliver another 75 bp hike in October and at least another 50 bp move in December. Many eurozone members are trying to protect households and small businesses from the surge in energy prices. The euro's decline exacerbates inflation, but the depreciation against the dollar overstates the case as the trade-weighted index has fallen by less than half as much. As widely expected, following the collapse of the Draghi government, Italy has elected among the most right-wing governments in modern times. The more conservative forces also won the Tory Party leadership contest and Sweden's general election. In anticipation of rising tensions with the EU, the premium demanded by investors for Italian assets has risen sharply. ECB President Lagarde has been explicit that the new Transmission Protection Instrument will not be used to save countries from their policy mistakes. This will be a potential flash point in the period ahead.


(September 30 indicative closing prices, previous in parentheses)


Spot: $0.9800 ($1.0055)

Median Bloomberg One-month Forecast $0.9800 ($1.0065)

One-month forward $0.9825 ($1.0025)   One-month implied vol 13.3% (10.3%)    



Japanese Yen:   The Bank of Japan increased the amount of 5–10-year bonds it regularly buys a couple of weeks before the Federal Reserve delivered a 75 bp hike and a hawkish message. Several hours after the FOMC meeting concluded last month, Governor Kuroda confirmed no change in BOJ policy. The dollar, which rose broadly after the Fed's decision, was almost at JPY146 when the Ministry of Finance ordered intervention to buy yen for the first time since 1998. The operation drove the dollar a little below JPY140.50. While late yen shorts felt the pressure, the underlying drivers (policy divergence and a negative terms-of-trade shock for Japan)- and sentiment have not changed. We suspect the market wants to challenge Japanese officials. The key is still US interest rates, which might help explain the decision to intervene against the odds. Japan is playing for time:  moderate the pace of decline as the peak in Fed policy and US rates are approached. 


Spot: JPY144.75 (JPY138.90)    

Median Bloomberg One-month Forecast JPY143.10 (JPY137.30)     

One-month forward JPY144.30 (JPY138.55) One-month implied vol 12.1% (11.1%)



British Pound: The Bank of England was the first G7 central bank to hike rates (2021), but the aggressiveness of the Fed and other major central banks left it behind and contributed to the weight on sterling. However, the mini-budget delivered by the new government was panned by economists and snubbed by investors. Sterling dropped like a ton of bricks to a new record low of about $1.0350. UK interest rates soared. The Bank of England has signaled a significant rate hike when it meets next in early November. The swaps market has nearly 150 bp discounted. Worried about the twin deficits (current account and budget), interest rates soared in a destabilizing fashion that threatened financial intermediaries, like pension funds. The Bank of England stepped and bought bonds. This, and the promise to hold back from selling bonds, which it had planned to begin in October as part of the effort to unwind the balance sheet that had expanded during the pandemic. The sentiment is extreme, and several banks now see sterling breaking below parity this year or early next year. We suspect this will prove to be an exaggeration.  


Spot: $1.1170 ($1.1625)   

Median Bloomberg One-month Forecast $1.1250 ($1.1700) 

One-month forward $1.1180 ($1.1630) One-month implied vol 18.5% (11.8%)



Canadian Dollar: The combination of the slowing of the Canadian economy and the drying of risk appetites (using the S&P 500 as a proxy) saw the Canadian dollar fall out of favor. The Canadian dollar fell to new two-year lows last month. The economy's outperformance in the first half is ending, helped by an aggressive central bank that surprised the market with a 100 bp hike in July and followed up with a 75 bp move in September. The swaps market anticipates a 50 bp hike in October and a 25 bp hike in December before the central bank pauses. The market looks for a terminal rate between 4.00%. This is to say that the Bank of Canada could be the first G10 central bank to reach its peak, possibly at the end of the year. The Canadian dollar's exchange rate continues to be sensitive to the general environment for risk. Stability in the US equities seems to be a precondition for a Canadian dollar recovery in October. Otherwise, the US dollar looks set to test the CAD1.40 area. 


Spot: CAD1.3830 (CAD 1.3130) 

Median Bloomberg One-month Forecast CAD1.3610 (CAD1.3070)

One-month forward CAD1.3835 (CAD1.3135)    One-month implied vol 11.4% (7.7%) 



Australian Dollar:  The Reserve Bank of Australia delivered its fourth consecutive 50 bp hike last month to lift the cash target rate to 2.35%. The impact of the hikes is beginning to materialize, and Governor Lowe has suggested that the pace of hikes may slow. With the weakness of the Australian dollar and with most central banks still moving in 50-75 bp increments, the market still favors another 50 bp hike at the October 4 meeting (~60%  probability). The terminal rate is seen around 4.00%-4.25% in mid-2023. Australia's two-year yield approached a 100 bp discount to the US, double what it was at the end of August. Since the mid-1980s, it has only once traded at more than a 100 bp discount (May 2019). The Australian dollar has broken through our $0.6600 objective and dropped to about $0.6365 before recovering. It needs to resurface above the $0.6550 area to take the pressure off the downside, which could extend toward $0.6200.  


Spot: $0.6400 ($0.6845)     

Median Bloomberg One-month Forecast $0.6540 ($0.6890)    

One-month forward $0.6405 ($0.6850)    One-month implied vol 16.4% (12.3%)   



Mexican Peso:  The peso was bowed by the dollar's surge last month. It still managed to eke out a minor gain  The currency had been less volatile than several G10 currencies. There was a fear last year that President AMLO was going to stack the central bank with doves, but this proved wide of the mark. As the Federal Reserve turned more aggressive, so did Banxico, and its reputation enhanced. It delivered a 75 bp hike in late September to 9.25%. The swaps market sees the terminal rate between 10.50% and 10.75%. If Banxico matches the Fed, it could be at 10.50% at the end of the year. The peso is still among the best-performing currencies this year, and yields on hedged and unhedged basis look lucrative. The Brazilian real has fared even better for the year as a whole (~4% vs. .2%)). Lula is expected to be elected President even if it requires a run-off. He appears chastened, and investors seem to still feel comfortable that moderate policies will be pursued.


Spot: MXN20.14 (MXN20.15)  

Median Bloomberg One-Month Forecast MXN20.19 (MXN20.24)  

One-month forward MXN20.25 (MXN20.27) One-month implied vol 12.3% (12.2%)



Chinese Yuan:  China is one of the few countries easing monetary policy. The divergence of monetary policy goes a long way toward explaining the pressure on the yuan. At the beginning of the year, for example, China's 10-year bond paid around 125 bp more than the US. Now, it is near a 100 bp discount. After trading broadly sideways in the first three-and-a-half months this year, officials accepted about a 6% depreciation of the yuan. There was another period of stability from mid-May until around mid-August. Since then, it has taken another leg lower. Though the end of September, the yuan has fallen by about 6.0%. The PBOC has moved to moderate the pace of the descent by cutting reserve requirements on foreign currency deposits, discouraging speculation, and consistently setting the dollar's reference rate below projections. The dollar is allowed to rise only 2% away from the fixing. Nevertheless, the divergence of policy can continue to weigh on the yuan. As the dollar pushed above CNY7.20 and as it probed the upper end of its band, the PBOC reportedly threatened to intervene directly in the foreign exchange market. The zero-Covid policy is taking a severe economic toll, and economists continue to revise down Chinese growth. Outside of the property market, the economy appears to be stabilizing, and the mid-September re-opening of Chengdu and Dalian may be reflected in next month's data. Rather than having to explain it away, as Xi takes a third term, he might use the economic challenges as a stick to stir up nationalistic sentiment.  


Spot: CNY7.1160 (CNY6.8900)

Median Bloomberg One-month Forecast CNY7.0755 (CNY6.8660) 

One-month forward CNY7.1025 (CNY6.8930) One-month implied vol 8.0% (5.6%)  





Read More

Continue Reading


Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…



To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading


Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….



Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 


About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. 

Read More

Continue Reading


Another country is getting ready to launch a visa for digital nomads

Early reports are saying Japan will soon have a digital nomad visa for high-earning foreigners.



Over the last decade, the explosion of remote work that came as a result of improved technology and the pandemic has allowed an increasing number of people to become digital nomads. 

When looked at more broadly as anyone not required to come into a fixed office but instead moves between different locations such as the home and the coffee shop, the latest estimate shows that there were more than 35 million such workers in the world by the end of 2023 while over half of those come from the United States.

Related: There is a new list of cities that are best for digital nomads

While remote work has also allowed many to move to cheaper places and travel around the world while still bringing in income, working outside of one's home country requires either dual citizenship or work authorization — the global shift toward remote work has pushed many countries to launch specific digital nomad visas to boost their economies and bring in new residents.

Japan is a very popular destination for U.S. tourists. 


This popular vacation destination will soon have a nomad visa

Spain, Portugal, Indonesia, Malaysia, Costa Rica, Brazil, Latvia and Malta are some of the countries currently offering specific visas for foreigners who want to live there while bringing in income from abroad.

More Travel:

With the exception of a few, Asian countries generally have stricter immigration laws and were much slower to launch these types of visas that some of the countries with weaker economies had as far back as 2015. As first reported by the Japan Times, the country's Immigration Services Agency ended up making the leap toward a visa for those who can earn more than ¥10 million ($68,300 USD) with income from another country.

The Japanese government has not yet worked out the specifics of how long the visa will be valid for or how much it will cost — public comment on the proposal is being accepted throughout next week. 

That said, early reports say the visa will be shorter than the typical digital nomad option that allows foreigners to live in a country for several years. The visa will reportedly be valid for six months or slightly longer but still no more than a year — along with the ability to work, this allows some to stay beyond the 90-day tourist period typically afforded to those from countries with visa-free agreements.

'Not be given a residence card of residence certificate'

While one will be able to reapply for the visa after the time runs out, this can only be done by exiting the country and being away for six months before coming back again — becoming a permanent resident on the pathway to citizenship is an entirely different process with much more strict requirements.

"Those living in Japan with the digital nomad visa will not be given a residence card or a residence certificate, which provide access to certain government benefits," reports the news outlet. "The visa cannot be renewed and must be reapplied for, with this only possible six months after leaving the countr

The visa will reportedly start in March and also allow holders to bring their spouses and families with them. To start using the visa, holders will also need to purchase private health insurance from their home country while taxes on any money one earns will also need to be paid through one's home country.

Read More

Continue Reading